preferred drug

Around 70% of South Korean key asset owners will expand their exposure to global private debt, expecting steady streams of cash flow, according to a r...

HK inno.N is expediting its global expansion with its latest drug K-Cab designed to treat peptic ulcers.The South Korean pharmaceutical company an...

South Korea’s Hanmi Pharmaceutical Co. generated sales of more than 1 trillion won ($812.3 million) from its own medicines last year on strong...

Healthcare and technology are the preferred sectors for global private equity investment, a survey of South Korea's major asset owners has shown. Co-i...

Healthcare and technology are the preferred sectors for global private equity investment, a survey of South Korea's major asset owners has shown. Co-i...

South Korea’s SK Chemicals plans to invest more than 2 trillion won ($1.6 billion) in eco-friendly material and biopharmaceutical businesses.T...

South Korea’s Hanmi Pharmaceutical Co. is set to launch its blockbuster high blood pressure drug Amosartan in China, the world’s largest...

South Korea’s biotechnology startup Voronoi Inc. is in talks with global biomedical companies on drug designs as it aims to expand the busines...

Lotte Group beat its retail rival Shinsegae Group in a competition to buy South Korea’s fifth-largest convenience store chain Ministop Korea. ...

Kolon TissueGene Inc., the cell therapies unit of South Korean pharmaceutical company Kolon Life Science Inc., said on Dec. 28 it has resumed admi...

South Korea’s HK inno.N Corp. has signed a 640 billion won ($540 million) contract to license out its technology for K-CAB, a gastroesophageal...

MedPacto Inc., a South Korean biotechnology company that develops therapeutics for cancer and autoimmune diseases, has agreed with global drugmaker ...

South Korea’s Celltrion Inc. has long been a biosimilar player, producing replicas of original drugs, a growing market in the pandemic era.Ear...

KKR & Co. has signed an agreement to buy 2.4 trillion won ($2 billion) worth of newly-issued preferred shares in SK E&S Co., the US private ...

A consortium led by electric bus maker Edison Motors Co. has been named the preferred buyer of South Korea’s troubled sport utility vehicle ma...

South Korean companies have built up their dollar holdings to record levels, following record-breaking shipment growth this year, as rising raw mate...

KKR & Co. has secured the exclusive negotiating rights to buy SK E&S Co.'s new preferred shares worth 2.4 trillion won ($2 billion), which t...

Samsung Bioepis Co., a leading South Korean biopharmaceutical company, has received approval from the US Food and Drug Administration for its Byoovi...

A number of new rare disease treatments, approved in South Korea over the past year, are still unaffordable for the public because of their price ta...

South Korea’s Samsung Biologics Co. is gearing up for the drug substance (DS) sector of the messenger ribonucleic acid (mRNA)-based COVID-19 v...

SK E&S Co., the largest city gas supplier in South Korea, has shortlisted four candidates among seven preliminary bidders to invest in 2 trillio...

KKR & Co., IMM Private Equity and Glenwood Private Equity are among the preliminary bidders for 2 trillion won ($1.9 billion) worth of new prefe...

South Korea-based Daewoong Pharmaceutical Co. is hoping to achieve 5 trillion won ($4.4 billion) in sales by 2027, meaning that the company aims to ...

The rise of the platform economy is a global phenomenon. The spread of the coronavirus pandemic has accelerated the use of contactless technology an...

South Korea’s SK Biopharmaceuticals Co. said on Friday it aspires to become one of the world’s top 10 healthcare companies by 2030 with ...

Eyegene Inc. will be South Korea’s first vaccine maker to conduct clinical tests of messenger ribonucleic acid (mRNA) COVID-19 vaccines. Ealie...

The sale of Citibank Korea’s consumer banking business is gaining traction as potential bidders have started due diligence of the bank, with e...

South Korea’s major convenience store chains are rushing to enter the Malaysian market. E-Mart 24, the convenience chain operated by Shinsegae...

South Korean biosimilar maker Celltrion Inc. and Mirae Asset Group have agreed to an investment that will render them the top shareholder in Iksuda ...

Samsung Biologics will be entering the drug substance segment of the COVID-19 vaccine contract manufacturing business. According to industry sources...